Number of lymph node metastases may indicate the regimen for adjuvant chemotherapy in patients with stage III colorectal cancer

Kouji Andou, Eiji Oki, Hiroshi Saeki, Yuta Kasagi, Yasuo Tsuda, Yoko Zaitsu, Yuichiro Nakashima, Yu Imamura, Kippei Ohgaki, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Background: Adjuvant chemotherapy (ACT) may prevent recurrence in patients with stage III colorectal cancer (CRC). However, only 10% of patients benefit from ACT and no effective indicators exist to predict which patients are likely to benefit. The present study validated metastatic lymph node (MLN) number as a new indicator for ACT. Patients and Methods: We retrospectively reviewed 173 patients with stage III CRC, who were classified by Union for International Cancer Control (UICC) stage or N category, and analyzed their overall survival (OS) and disease-free survival (DFS) according to stage, number of MLNs and ACT use. Results: Among 173 patients, we found 65 with only one MLN (N1a). For N1a patients treated with ACT, the 5-year OS rate was 100%; the 3-year DFS rate was 92.7% for those treated with oral ACT. Conclusion: The number of MLNs is a simple indicator for ACT in patients with stage III CRC. For patients with only one MLN, oral chemotherapy is a good option.

元の言語英語
ページ(範囲)6207-6211
ページ数5
ジャーナルAnticancer Research
35
発行部数11
出版物ステータス出版済み - 11 1 2015

Fingerprint

Adjuvant Chemotherapy
Colorectal Neoplasms
Lymph Nodes
Neoplasm Metastasis
Disease-Free Survival
Survival Rate
Recurrence
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Number of lymph node metastases may indicate the regimen for adjuvant chemotherapy in patients with stage III colorectal cancer. / Andou, Kouji; Oki, Eiji; Saeki, Hiroshi; Kasagi, Yuta; Tsuda, Yasuo; Zaitsu, Yoko; Nakashima, Yuichiro; Imamura, Yu; Ohgaki, Kippei; Maehara, Yoshihiko.

:: Anticancer Research, 巻 35, 番号 11, 01.11.2015, p. 6207-6211.

研究成果: ジャーナルへの寄稿記事

Andou, K, Oki, E, Saeki, H, Kasagi, Y, Tsuda, Y, Zaitsu, Y, Nakashima, Y, Imamura, Y, Ohgaki, K & Maehara, Y 2015, 'Number of lymph node metastases may indicate the regimen for adjuvant chemotherapy in patients with stage III colorectal cancer', Anticancer Research, 巻. 35, 番号 11, pp. 6207-6211.
Andou, Kouji ; Oki, Eiji ; Saeki, Hiroshi ; Kasagi, Yuta ; Tsuda, Yasuo ; Zaitsu, Yoko ; Nakashima, Yuichiro ; Imamura, Yu ; Ohgaki, Kippei ; Maehara, Yoshihiko. / Number of lymph node metastases may indicate the regimen for adjuvant chemotherapy in patients with stage III colorectal cancer. :: Anticancer Research. 2015 ; 巻 35, 番号 11. pp. 6207-6211.
@article{40d8b12e5fbc401c89e345e27fb0dbfe,
title = "Number of lymph node metastases may indicate the regimen for adjuvant chemotherapy in patients with stage III colorectal cancer",
abstract = "Background: Adjuvant chemotherapy (ACT) may prevent recurrence in patients with stage III colorectal cancer (CRC). However, only 10{\%} of patients benefit from ACT and no effective indicators exist to predict which patients are likely to benefit. The present study validated metastatic lymph node (MLN) number as a new indicator for ACT. Patients and Methods: We retrospectively reviewed 173 patients with stage III CRC, who were classified by Union for International Cancer Control (UICC) stage or N category, and analyzed their overall survival (OS) and disease-free survival (DFS) according to stage, number of MLNs and ACT use. Results: Among 173 patients, we found 65 with only one MLN (N1a). For N1a patients treated with ACT, the 5-year OS rate was 100{\%}; the 3-year DFS rate was 92.7{\%} for those treated with oral ACT. Conclusion: The number of MLNs is a simple indicator for ACT in patients with stage III CRC. For patients with only one MLN, oral chemotherapy is a good option.",
author = "Kouji Andou and Eiji Oki and Hiroshi Saeki and Yuta Kasagi and Yasuo Tsuda and Yoko Zaitsu and Yuichiro Nakashima and Yu Imamura and Kippei Ohgaki and Yoshihiko Maehara",
year = "2015",
month = "11",
day = "1",
language = "English",
volume = "35",
pages = "6207--6211",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Number of lymph node metastases may indicate the regimen for adjuvant chemotherapy in patients with stage III colorectal cancer

AU - Andou, Kouji

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Kasagi, Yuta

AU - Tsuda, Yasuo

AU - Zaitsu, Yoko

AU - Nakashima, Yuichiro

AU - Imamura, Yu

AU - Ohgaki, Kippei

AU - Maehara, Yoshihiko

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background: Adjuvant chemotherapy (ACT) may prevent recurrence in patients with stage III colorectal cancer (CRC). However, only 10% of patients benefit from ACT and no effective indicators exist to predict which patients are likely to benefit. The present study validated metastatic lymph node (MLN) number as a new indicator for ACT. Patients and Methods: We retrospectively reviewed 173 patients with stage III CRC, who were classified by Union for International Cancer Control (UICC) stage or N category, and analyzed their overall survival (OS) and disease-free survival (DFS) according to stage, number of MLNs and ACT use. Results: Among 173 patients, we found 65 with only one MLN (N1a). For N1a patients treated with ACT, the 5-year OS rate was 100%; the 3-year DFS rate was 92.7% for those treated with oral ACT. Conclusion: The number of MLNs is a simple indicator for ACT in patients with stage III CRC. For patients with only one MLN, oral chemotherapy is a good option.

AB - Background: Adjuvant chemotherapy (ACT) may prevent recurrence in patients with stage III colorectal cancer (CRC). However, only 10% of patients benefit from ACT and no effective indicators exist to predict which patients are likely to benefit. The present study validated metastatic lymph node (MLN) number as a new indicator for ACT. Patients and Methods: We retrospectively reviewed 173 patients with stage III CRC, who were classified by Union for International Cancer Control (UICC) stage or N category, and analyzed their overall survival (OS) and disease-free survival (DFS) according to stage, number of MLNs and ACT use. Results: Among 173 patients, we found 65 with only one MLN (N1a). For N1a patients treated with ACT, the 5-year OS rate was 100%; the 3-year DFS rate was 92.7% for those treated with oral ACT. Conclusion: The number of MLNs is a simple indicator for ACT in patients with stage III CRC. For patients with only one MLN, oral chemotherapy is a good option.

UR - http://www.scopus.com/inward/record.url?scp=84946029310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946029310&partnerID=8YFLogxK

M3 - Article

C2 - 26504052

AN - SCOPUS:84946029310

VL - 35

SP - 6207

EP - 6211

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -